Stay updated on GLE/PIB in Treatment-Naive Cirrhotic HCV: Clinical Trial

Sign up to get notified when there's something new on the GLE/PIB in Treatment-Naive Cirrhotic HCV: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the GLE/PIB in Treatment-Naive Cirrhotic HCV: Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a shift in the historical SVR12 rates of 8 weeks of treatment with glecaprevir/pibrentasvir compared to the previous 12 weeks of treatment with the same medication for adults with chronic HCV infection and compensated cirrhosis.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:29.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the required health conditions and prior treatments for inclusion in the study. Previously, this section had no information provided.
    Difference
    9%
    Check dated 2024-05-22T21:11:04.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:24:57.000Z thumbnail image

Stay in the know with updates to GLE/PIB in Treatment-Naive Cirrhotic HCV: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the GLE/PIB in Treatment-Naive Cirrhotic HCV: Clinical Trial page.